Twiggy can this..., page-21

The last annual report (July to Dec 2017) reported on four divisions:

1 - Medical products and devices
2 - Bio implant operations
3 - Regenerative medicine R&D
4- Immunotherapies R&D

It showed that immunotherapies had zero revenue and a loss of $852,422 for the six months from July to Dec 2017.

Immunotherapy assets, as you say, were $4.79. Also, as you say, most of that would be IP. I don't know how much cash is on its books and when AHZ last topped up their share of the costs.

But if they lose say $852k * 2 = $1.7 million per annum, AHZ's pro-rata share of these costs would be 72.8% of these costs.

What I wonder is how much they tipped in (if anything) for these costs in the last few quarters. Surely there isn't much cash in the immunotherapy account to have not required top ups from AHZ for that long.